A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:
A) Decreased effectiveness of irinotecan in the treatment of cancer
B) Increased adverse drug reactions, such as neutropenia
C) Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
D) Increased concerns for irinotecan being carcinogenic
Correct Answer:
Verified
Q2: Inhibition of P-glycoprotein by a drug such
Q3: Carbamazepine has a black box warning recommending
Q4: Rifampin is a nonspecific CYP450 inducer that
Q5: Genetic polymorphisms account for differences in metabolism,
Q6: Warfarin resistance may be seen in patients
Q7: Genetic testing for a VKORC1 mutation to
Q8: Ultra-rapid metabolizers of drugs may have:
A)To have
Q9: Up to 21% of Asians are ultra-rapid
Q10: Pharmacogenetic testing is required by the U.S.
Q11: A provider may consider testing for CYP2D6
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents